Looking at Gum Bacteria in Systemic Sclerosis
Studies gum bacteria in people with and without systemic sclerosis.
Plain-language title generated from the registry record
Registry title: Periodontal Microbiota in Systemic Sclerosis
Key facts
- Where
- Strasbourg, FranceSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with systemic sclerosis diagnosed in the last 2 years, and adults without it who come for a routine dental visit. Everyone needs more than 12 teeth that can be checked.
- Age
- 18 years or older
- Sex
- Men and women
- Disease stage
- Systemic sclerosis diagnosed in the 2 years before joining (early disease). Controls come for a routine dental visit.
- Earlier treatment
- No antibiotic or antifungal treatment in the 3 months before joining. No probiotics or prebiotics in the 3 months before. No mouthwash antiseptic in the week before. No special gum treatment in the year before.
Main reasons for not taking part
- Pregnant or breastfeeding
- Smoking 10 or more cigarettes per day
- Another autoimmune disease or other ongoing chronic illness
- Corticosteroids of 10 mg/day or more, or proton pump inhibitors, in the last 3 months
- Earlier stem-cell transplant
Read by machine on 12 November 2026.
Where in France
- Clinique DentaireStrasbourg, FranceContact: Sophie JUNG, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University Hospital, Strasbourg, France
- Trial code
- NCT06182293
- Record updated
- 19 August 2026
- Original description
Systemic sclerosis (SSc) is a rare and complex autoimmune disease. Although its etiology remains unknown, various environmental factors, including certain microorganisms, can represent potential triggers of SSc in individuals with a permissive genetic background. Patients show a wide spectrum of clinical features including periodontitis, which is an inflammatory disease of the tooth-supporting tissues resulting from dysbiosis of the periodontal microbiota guided by inflammophilic bacteria.Read full original descriptionShow less
Impact of Systemic Sclerosis on the Periodontal Microbiota: a Pilot Study
Systemic sclerosis (SSc) is a rare and complex autoimmune disease. Although its etiology remains unknown, various environmental factors, including certain microorganisms, can represent potential triggers of SSc in individuals with a permissive genetic background. Patients show a wide spectrum of clinical features including periodontitis, which is an inflammatory disease of the tooth-supporting tissues resulting from dysbiosis of the periodontal microbiota guided by inflammophilic bacteria.
The microbiota plays a fundamental role in the induction, training, and function of the host immune system. Numerous studies have highlighted the impact of an altered microbiota, i.e. dysbiosis, on the pathogenesis of immune-mediated diseases. Indeed, commensals are important to maintain immune homeostasis and changes in the microbial composition can be responsible for a loss of tolerance. SSc has been shown to be associated with gut dysbiosis and a depletion of commensals. However, although the oral cavity is one of the two largest microbial habitats, only one study (only focusing on Lactobacillus species) has investigated the oral microbiota in SSc. As periodontal dysbiosis is known to induce low-grade systemic inflammation and represents a risk factor for the development of various autoimmune diseases, the relationship between periodontal microbiota composition and SSc merits further exploration.
The aim of this pilot study is to characterize the taxonomic composition and metabolic pathways of the periodontal microbiota in SSc patients and age and sex-matched controls.
Inclusion: Common inclusion criteria; Men or women over 18 (adults); Affiliation to a social health insurance plan; Subject able to understand the aims and risks of the research and to give signed informed consent form prior to the inclusion in the study; More than 12 teeth suitable for evaluation; Systemic sclerosis patient with a diagnosis based on the American College of Rheumatology/European League Against Rheumatism criteria (LeRoy et al., 1988 ; van den Hoogen et al., 2013); Diagnosis made during the 2 years preceding study inclusion (early form of the disease); Patient attending the Oral Medicine and Surgery Department from the University Hospital of Strasbourg for a routine dental consultation.
Exclusion: Progressive cancer or cancer diagnosed within 2 years prior to the study; Ongoing antibiotic and/or antifungal treatment or within 3 months prior to inclusion; Probiotics and/or prebiotics intake within 3 months prior to inclusion; Oral antiseptics within the week before inclusion (chlorhexidin mouthwashes…); Corticosteroids ≥10 mg/day and/or proton pump inhibitors within 3 months prior to inclusion; Previous hematopoietic stem cell transplantation; Another cause of skin sclerosis (radiotherapy of the orofacial area…); Periodontal specialized treatments, root and/or periodontal surgical treatment and/or subgingival instrumentation within the year before inclusion; Progressive chronic illness other than systemic sclerosis; Acute infection at inclusion; Other associated systemic auto-immune disease (Sjögren syndrome with positive serum anti-SSA and/or anti-SSB auto-antibodies, systemic lupus erythematosus…); - Subject under court protection; Subject under guardianship or curatorship; Pregnancy or breastfeeding; Impossibility to provide accurate information (emergency situation, comprehension difficulties…); Subject currently involved in another clinical trial or in an exclusion period following participation in another clinical trial; Smoking (≥ 10 cigarettes per day); Risk of infective endocarditis.